UBS Rates Accretive Health Buy

UBS (NYSE:UBS) initiated coverage of Accretive Health (NYSE:AH) with a rating of Buy and a price target of $29. The shares recently traded at $23.04, up $0.89 or 4.02%, on the day.  The shares have traded in a 52-week range of $8.30 to $32.82 and its market capitalization is $2.25 billion.  About the company: Accretive Health, Inc. offers health care revenue cycle consulting services. The Company helps its customers avoid bad debt write-offs, uncompensated care, payor denials and corresponding administrative write-offs, and lost revenue for missed charges.

(Note: Stock ratings are sourced from Briefing.com via the Wall St. Journal.  Selected financial data are sourced from Google Finance.  All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>